Clinical trial leads to FDA approval of drug for rare, deadly blood cancer
Fewer than half of people diagnosed with a subtype of myeloid/lymphoid neoplasms are alive one year later. A multicenter Phase II trial, called FIGHT-203, led by Stanford Medicine, has led to FDA approval of a new drug treatment.
Aug 28, 2025
0
24









